{"url_path":"/sec/bioe/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1723059/0001213900-26-057529-index.html","accession_number":"0001213900-26-057529","cik":"0001723059","ticker":"BIOE","issuer_name":"Bio Essence Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1723059/0001213900-26-057529-index.html","primary_entity_key":"0001723059","primary_entity_name":"Bio Essence Corp"},"word_count":132,"has_tables":true,"body_markdown":"**Item\n1. Legal Proceedings.**\n\n \n\nOn\nor about February 27, 2026, Stason Industrial Corporation (“SIC”) and Stason Pharmaceuticals, Inc. (“SPI,” collectively\n“Stason”) filed a Complaint in the Superior Court of Orange County, in California (the “Complaint”), alleging\nthat the Company breached its contract and lease obligations relating to a large commercial space previously utilized by the Company.\nThe Company and ten (10) unidentified individuals are defendants of the case. The Complaint alleges that the Company breached rental\npayment obligations, and accrued late fees and other penalties pursuant to the operative agreements. The Complaint seeks $1,504,823.81\nin damages as of January of 2026. The Company denies the allegations and is in the process of retaining legal counsel. The Company intends\non bringing counterclaims and affirmative defenses relating to first material breaches committed by Stason."}